



DTRF Annual Patient Meeting


Casey Cunningham, M.D.

Chief Medical Officer

September 21, 2019

What is Tegavivint?


- Tegavivint is given as a once-weekly intravenous infusion that has been shown to decrease beta-catenin protein levels.
- Desmoid tumors are known to solely be caused by elevated beta-catenin protein.
- So, Tegavivint specifically targets the root cause of desmoid tumors



Phase 1/2a clinical study enrolling patients

- Open-label, multi-center, non-randomized study to evaluate safety of Tegavivint in patients with a desmoid tumor that is unresectable and symptomatic or progressive.
- Once weekly intravenous infusion. Three weeks on drug followed by a week off.
- Enrolling at six centers in United States and one in Canada.
- Currently enrolling 6th cohort in Phase I dose escalation portion of study.
- All patients participating in Phase I will have the choice to automatically escalate to the recommended phase 2 dose (RP2D) when we transition to the Phase 2a expansion phase of study, which will include 25 patients.
- For more information please visit <https://clinicaltrials.gov/ct2/show/NCT03459469?term=tegavivint&rank=1>

Tumor Growth



- Twelve patients have been treated by drug with 10 months being the longest treatment time
- No significant drug related side effect reported
- Patient receive MRI scan every three months
- All treated patients have stable disease with decreasing tumor size in those that have received at least six cycles on drug
- Due to low toxicity profile and preliminary efficacy, patients and physicians requested that we amend clinical protocol to allow for up to two years of treatment

Currently enrolling clinical centers

Institution	Investigator	Study Coordinator
Princess Margaret Cancer Centre (Toronto, ON)	Albiruni Razak, MD	Horace Wong, MSc, HonBSc horace.wong@uhn.ca
Dana Farber Cancer Institute (Boston, MA)	Suzanne George, MD	Abigail Porcello aporcello@partners.org
Massachusetts General Hospital (Boston, MA)	Edwin Choy, MD	Lia Tamburello lmtamburello@mgh.harvard.edu
Seattle Cancer Care Alliance (Seattle WA)	Lee Cranmer, MD	Roxanne Moore romoore@seattlecca.org
MD Anderson Cancer Center (Houston, TX)	Vinod Ravi, MD Shreyaskumar Patel, MD	Giberto Botello GBotello@mdanderson.org
Memorial Sloan Kettering Cancer Center (New York, NY)	Mrinal Gounder, MD	Moriah Martindale martindm@mskcc.org
The Ohio State University Comprehensive Cancer Center (Columbus, OH)	David Liebner, MD	Cassandra Faiella Cassandra.Faiella@osumc.edu